{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T14:47:01Z","timestamp":1743346021114,"version":"3.40.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-025-01160-0","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T04:56:42Z","timestamp":1742533002000},"page":"61-70","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Once-Nightly Sodium Oxybate in Patients with Narcolepsy: Post Hoc Analyses of Sensitivity, Effect Size, and Numbers Needed to Treat from the Phase 3 REST-ON Trial"],"prefix":"10.1007","volume":"39","author":[{"given":"Thomas","family":"Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clete A.","family":"Kushida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7375-5020","authenticated-orcid":false,"given":"Jennifer","family":"Gudeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1160_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/sleep\/30.1.13","volume":"30","author":"WT Longstreth Jr","year":"2007","unstructured":"Longstreth WT Jr, Koepsell TD, Ton TG, et al. The epidemiology of narcolepsy. Sleep. 2007;30:13\u201326.","journal-title":"Sleep"},{"key":"1160_CR2","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373:2654\u201362.","journal-title":"N Engl J Med"},{"key":"1160_CR3","doi-asserted-by":"publisher","first-page":"100095","DOI":"10.1016\/j.sleepx.2023.100095","volume":"6","author":"MM Ohayon","year":"2023","unstructured":"Ohayon MM, Duhoux S, Grieco J, Cote ML. Prevalence and incidence of narcolepsy symptoms in the US general population. Sleep Med X. 2023;6:100095.","journal-title":"Sleep Med X"},{"key":"1160_CR4","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/ene.14888","volume":"28","author":"CLA Bassetti","year":"2021","unstructured":"Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28:2815\u201330.","journal-title":"Eur J Neurol"},{"key":"1160_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:1881\u201393.","journal-title":"J Clin Sleep Med"},{"unstructured":"Avadel Pharmaceuticals. LUMRYZ\u2122 (sodium oxybate for extended-release oral suspension, CIII). Full prescribing information. Chesterfield: Avadel Pharmaceuticals; 2024.","key":"1160_CR6"},{"doi-asserted-by":"crossref","unstructured":"Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45:zsab200.","key":"1160_CR7","DOI":"10.1093\/sleep\/zsab200"},{"key":"1160_CR8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","volume":"36","author":"T Roth","year":"2022","unstructured":"Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial. CNS Drugs. 2022;36:377\u201387.","journal-title":"CNS Drugs"},{"key":"1160_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1191\/1740774504cn032oa","volume":"1","author":"AM Wood","year":"2004","unstructured":"Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials. 2004;1:368\u201376.","journal-title":"Clin Trials"},{"key":"1160_CR10","first-page":"e31","volume":"3","author":"FJ Molnar","year":"2009","unstructured":"Molnar FJ, Man-Son-Hing M, Hutton B, Fergusson DA. Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. Open Med. 2009;3:e31-50.","journal-title":"Open Med"},{"key":"1160_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","volume":"62","author":"G Kemmler","year":"2005","unstructured":"Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305\u201312.","journal-title":"Arch Gen Psychiatry"},{"doi-asserted-by":"crossref","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44:zsaa206.","key":"1160_CR12","DOI":"10.1093\/sleep\/zsab188"},{"key":"1160_CR13","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","volume":"367","author":"RJ Little","year":"2012","unstructured":"Little RJ, D\u2019Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355\u201360.","journal-title":"N Engl J Med"},{"key":"1160_CR14","volume-title":"The prevention and treatment of missing data in clinical trials","author":"National Research Council","year":"2010","unstructured":"National Research Council. The prevention and treatment of missing data in clinical trials. Washington: The National Academies Press; 2010."},{"key":"1160_CR15","first-page":"26","volume":"11","author":"L Citrome","year":"2014","unstructured":"Citrome L. Quantifying clinical relevance. Innov Clin Neurosci. 2014;11:26\u201330.","journal-title":"Innov Clin Neurosci"},{"unstructured":"American Academy of Sleep Medicine. International classification of sleep disorders. 3rd ed. Darien: American Academy of Sleep Medicine; 2014.","key":"1160_CR16"},{"key":"1160_CR17","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4300\/JGME-D-12-00156.1","volume":"4","author":"GM Sullivan","year":"2012","unstructured":"Sullivan GM, Feinn R. Using effect size-or why the P value is not enough. J Grad Med Educ. 2012;4:279\u201382.","journal-title":"J Grad Med Educ"},{"key":"1160_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/1471-2288-13-92","volume":"13","author":"L Thabane","year":"2013","unstructured":"Thabane L, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92.","journal-title":"BMC Med Res Methodol"},{"key":"1160_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1080\/10543406.2022.2058525","volume":"32","author":"A Gorst-Rasmussen","year":"2022","unstructured":"Gorst-Rasmussen A, Tarp-Johansen MJ. Fast tipping point sensitivity analyses in clinical trials with missing continuous outcomes under multiple imputation. J Biopharm Stat. 2022;32:942\u201353.","journal-title":"J Biopharm Stat"},{"unstructured":"Jazz Pharmaceuticals. Xyrem\u00ae (sodium oxybate). Full prescribing information. Palo Alto: Jazz Pharmaceuticals, Inc; 2023.","key":"1160_CR20"},{"unstructured":"Jazz Pharmaceuticals. Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybate). Full prescribing information. Palo Alto: Jazz Pharmaceuticals, Inc; 2023.","key":"1160_CR21"},{"key":"1160_CR22","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","volume":"319","author":"S Hollis","year":"1999","unstructured":"Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670\u20134.","journal-title":"BMJ"},{"key":"1160_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/1471-2288-14-118","volume":"14","author":"ML Bell","year":"2014","unstructured":"Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol. 2014;14:118.","journal-title":"BMC Med Res Methodol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01160-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T14:23:55Z","timestamp":1743344635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":23,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1160"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01160-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"type":"print","value":"1172-7047"},{"type":"electronic","value":"1179-1934"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"15 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article has been published as part of a journal supplement wholly funded by Avadel Pharmaceuticals (Chesterfield, MO, USA). This study was funded by Avadel Pharmaceuticals. Avadel Pharmaceuticals was involved in the study design, collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.\u00a0Open access publication and publication costs were funded by Avadel Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TR is a consultant for Jazz Pharmaceuticals, Takeda Pharmaceutical Co., Orexo, Avadel Pharmaceuticals, Eisai, Merck & Co., and Idorsia. MJT is the guest editor of this supplement and played no part in the peer review or decision making of this article at the editorial level and contributed solely as an author. He has served as a consultant or on advisory boards for Axsome Therapeutics, Balance Therapeutics, Eisai, Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharmaceuticals, NLS Pharmaceuticals, Suven Life Sciences Ltd, and Takeda Pharmaceutical Co. CAK is a consultant for Avadel Pharmaceuticals and XW Pharma. JG is an employee of Avadel Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Institutional review board or independent ethics committee approval was obtained for each study center.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was provided by all adult participants (\u2265 18 years old); consent was obtained from both the participant and their legally authorized representative for participants 16 and 17 years of age.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Thomas Roth: Writing \u2013 review and editing, formal analysis. Michael J. Thorpy: Writing \u2013 review and editing, formal analysis. Clete A. Kushida: Writing \u2013 review and editing, formal analysis. Jennifer Gudeman: Writing \u2013 review and editing, formal analysis.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contribution"}}]}}